We also studied the molecular mechanism and showed that Kremen2 bound to SOCS3 to inhibit SOCS3-mediated EGFR degradation and promote activation of the EGFR signaling pathway, which exacerbated the malignant progression of NSCLC (Fig. 7). This evidence concerns the gene KREMEN2 and non-small cell lung carcinoma.